Benchmark Lowers Humacyte (NASDAQ:HUMA) Price Target to $10.00

Humacyte (NASDAQ:HUMA) had its target price dropped by analysts at Benchmark from $11.00 to $10.00 in a report released on Wednesday, Marketbeat Ratings reports. The firm currently has a “buy” rating on the stock.

Other equities analysts also recently issued research reports about the stock. D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research note on Monday, January 5th. Wall Street Zen cut shares of Humacyte from a “hold” rating to a “sell” rating in a research note on Sunday, December 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Humacyte in a report on Monday, December 29th. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Humacyte in a report on Monday, December 1st. Finally, BTIG Research restated a “buy” rating and set a $6.00 target price on shares of Humacyte in a research report on Friday, November 21st. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $8.14.

Humacyte Stock Performance

Shares of HUMA opened at $1.12 on Wednesday. Humacyte has a 1 year low of $0.91 and a 1 year high of $4.85. The company has a debt-to-equity ratio of 2.97, a current ratio of 1.62 and a quick ratio of 0.90. The stock’s fifty day moving average price is $1.16 and its two-hundred day moving average price is $1.60. The firm has a market cap of $209.74 million, a PE ratio of -4.87 and a beta of 1.93.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.03. The firm had revenue of $0.75 million during the quarter, compared to analysts’ expectations of $0.92 million. On average, equities research analysts forecast that Humacyte will post -1.27 EPS for the current year.

Institutional Trading of Humacyte

Institutional investors and hedge funds have recently bought and sold shares of the company. Pallas Capital Advisors LLC bought a new position in Humacyte in the 2nd quarter valued at $42,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of Humacyte in the second quarter worth $49,000. Wealth Effects LLC raised its position in shares of Humacyte by 5.8% in the second quarter. Wealth Effects LLC now owns 102,167 shares of the company’s stock worth $214,000 after buying an additional 5,600 shares in the last quarter. Lazari Capital Management Inc. bought a new stake in Humacyte during the second quarter valued at $27,000. Finally, Archford Capital Strategies LLC bought a new stake in Humacyte during the second quarter valued at $42,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.